News coverage about Puma Biotechnology (NASDAQ:PBYI) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Puma Biotechnology earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 47.414925947771 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Puma Biotechnology (NASDAQ:PBYI) opened at $74.70 on Friday. The company has a current ratio of 1.82, a quick ratio of 1.23 and a debt-to-equity ratio of 0.91. The stock has a market cap of $2,800.69, a PE ratio of -9.52 and a beta of 0.26. Puma Biotechnology has a 1 year low of $28.35 and a 1 year high of $136.90.
Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.98) by $0.27. The business had revenue of $21.60 million for the quarter, compared to analysts’ expectations of $20.83 million. During the same quarter in the prior year, the company posted ($1.22) earnings per share. sell-side analysts anticipate that Puma Biotechnology will post -3.86 earnings per share for the current fiscal year.
Several analysts have commented on the stock. Zacks Investment Research cut shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. Credit Suisse Group set a $142.00 target price on shares of Puma Biotechnology and gave the company a “buy” rating in a research report on Monday, January 15th. ValuEngine cut shares of Puma Biotechnology from a “hold” rating to a “sell” rating in a research report on Wednesday, January 3rd. Citigroup restated a “buy” rating and set a $164.00 target price on shares of Puma Biotechnology in a research report on Wednesday, January 3rd. Finally, Royal Bank of Canada decreased their target price on shares of Puma Biotechnology to $77.00 and set a “sector perform” rating on the stock in a research report on Wednesday, January 24th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $103.11.
In related news, insider Alan H. Auerbach sold 10,692 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $92.75, for a total transaction of $991,683.00. Following the transaction, the insider now directly owns 4,155,931 shares in the company, valued at approximately $385,462,600.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Richard Paul Bryce sold 1,860 shares of the company’s stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $92.75, for a total transaction of $172,515.00. Following the transaction, the senior vice president now owns 25,379 shares in the company, valued at $2,353,902.25. The disclosure for this sale can be found here. Corporate insiders own 21.10% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Puma Biotechnology (PBYI) Share Price” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/03/17/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-puma-biotechnology-pbyi-share-price.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.